| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/09/2006 | US7041282 Ligands for flt3 receptors |
| 05/09/2006 | CA2257328C Thiazole derivatives |
| 05/09/2006 | CA2175687C A bacterial nitroreductase gene-prodrug system |
| 05/09/2006 | CA2156857C Human b-lymphoblastoid cell line secreting anti-ganglioside antibody |
| 05/09/2006 | CA1341505C Intravenously administered polyclonal immunoglobulin preparation containing igm and method of manufacture |
| 05/04/2006 | WO2006047759A2 Kinase inhibitors for the treatment of diabetes and obesity |
| 05/04/2006 | WO2006047744A2 Compositions of lactoferrin related peptides and uses thereof |
| 05/04/2006 | WO2006047684A2 Tissue factor phospholipid vesicle particles and methods of use for coagulation |
| 05/04/2006 | WO2006047637A1 Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections |
| 05/04/2006 | WO2006047635A2 Methods and compositions for seprase inactivation |
| 05/04/2006 | WO2006047625A2 Method to promote wound healing |
| 05/04/2006 | WO2006047579A2 Vitamin e tpgs fluid concentrate comprising a low percentage of water |
| 05/04/2006 | WO2006047535A2 Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| 05/04/2006 | WO2006047312A2 COMPOSITIONS AND METHODS FOR MODULATING PGC-1β TO TREAT LIPID-RELATED DISEASES AND DISORDERS |
| 05/04/2006 | WO2006047242A2 Duffy antigen receptor for chemokines and use thereof |
| 05/04/2006 | WO2006047172A1 Tweak receptor |
| 05/04/2006 | WO2006047080A1 Presbyopia treatment by lens alteration |
| 05/04/2006 | WO2006046978A2 Cationic peptide-mediated transformation |
| 05/04/2006 | WO2006046977A1 Macrocyclic ghrelin receptor antagonists and methods of using the same |
| 05/04/2006 | WO2006046880A1 Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal |
| 05/04/2006 | WO2006046847A1 Composition for the treatment of obesity and hyperlipidaemia |
| 05/04/2006 | WO2006046766A1 Gene therapy for treatment of cardiac failure |
| 05/04/2006 | WO2006046735A1 Novel aminopyridine derivatives having aurora a selective inhibitory action |
| 05/04/2006 | WO2006046626A1 Water-soluble elastins, process for producing the same, and food and medicine containing the same |
| 05/04/2006 | WO2006046613A1 Il-18-like peptide, fused peptide thereof, method of producing the same and use of the same |
| 05/04/2006 | WO2006046603A1 Islet transplantation auxiliary |
| 05/04/2006 | WO2006046584A1 Remedy for visual cell injuries |
| 05/04/2006 | WO2006046569A1 Neuronal differentiation promoting peptide |
| 05/04/2006 | WO2006046250A2 Compositions and methods for diagnosing and treating insulin resistance |
| 05/04/2006 | WO2006046073A2 C1q related protein |
| 05/04/2006 | WO2006046072A2 VWFA AND/OR ANT_IG DOMAIN CONTAINING PROTEINS |
| 05/04/2006 | WO2006046065A1 Botulinum toxin therapy of heart rhythm disorders |
| 05/04/2006 | WO2006045939A1 Modulating synaptic transmission by semaphorins and applications thereof |
| 05/04/2006 | WO2006045891A1 Avidin-like proteins from symbiotic bacteria |
| 05/04/2006 | WO2006045820A1 Pharmaceutical compositions based on nk2 antagonists for pediatric use |
| 05/04/2006 | WO2006045677A1 Hcv vaccines for chronic hcv patients |
| 05/04/2006 | WO2006045591A2 Method and constructs for delivering double stranded rna to pest organisms |
| 05/04/2006 | WO2006045319A2 Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure |
| 05/04/2006 | WO2006045313A2 Uses of secretagogues for treatment of organ transplant patients |
| 05/04/2006 | WO2006045156A1 Therapy for multi-drug resistant microorganisms |
| 05/04/2006 | WO2006032525A3 Combinational therapy for treating cancer |
| 05/04/2006 | WO2006026998A8 Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis |
| 05/04/2006 | WO2006026678A3 Method for downregulating an immune reaction |
| 05/04/2006 | WO2006023029A3 The cysteine-rich region of respiratory syncytial virus and methods of use therefor |
| 05/04/2006 | WO2006018632A3 Cell therapy with exo 1 |
| 05/04/2006 | WO2006017715A3 Methods of determining immunoresistance to botulinum toxin a |
| 05/04/2006 | WO2006017456A3 Chymopapain isoenzymes, compositions, and uses thereof |
| 05/04/2006 | WO2006015385A3 Anti-angiogenic peptides and methods of use thereof |
| 05/04/2006 | WO2006009809A3 Vegf inhibitors for the treatment of malignant pleural effusion |
| 05/04/2006 | WO2006006172A3 Use of anti-amyloid agents for treating and typing pathogen infections |
| 05/04/2006 | WO2006005461A3 Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 27 (gpr27) |
| 05/04/2006 | WO2006004675A3 Production of tissue factor in plants |
| 05/04/2006 | WO2006003488A3 Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
| 05/04/2006 | WO2005123108A3 Advanced vitamins and protein based nutritional supplements |
| 05/04/2006 | WO2005121174A3 Novel g-csf polypeptides, polynucleotides, modulators thereof, and methods of use |
| 05/04/2006 | WO2005118628A3 Nucleic acid molecules encoding plant cyclotide polypeptides and methods of use |
| 05/04/2006 | WO2005117950A3 Regulation of glucose and insulin levels by gnt-4 glycosyltransferase activity |
| 05/04/2006 | WO2005115432A3 Treatment of ocular diseases and disorders using lantibiotic compositions |
| 05/04/2006 | WO2005113606A3 Fgf-21 fusion proteins |
| 05/04/2006 | WO2005113236A3 Films comprising a liquid-absorbant inner layer, an antimicrobial material and an impermeable outer layer |
| 05/04/2006 | WO2005112546A3 Mucinous glycoprotein (muc-1) vaccine |
| 05/04/2006 | WO2005110453A3 Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1 |
| 05/04/2006 | WO2005108416A3 Myosin light chain kinase inhibitors and their use |
| 05/04/2006 | WO2005106492A3 Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3) |
| 05/04/2006 | WO2005089398A3 Method for the delivery of sustained release agents |
| 05/04/2006 | WO2005086827A3 Methods of assessing the need for and the effectiveness of therapy with antioxidants |
| 05/04/2006 | WO2005084198A3 Peptides of il1 beta and tnf alpha and method of treatment using same |
| 05/04/2006 | WO2005082109A3 Solution additives for the attenuation of protein aggregation |
| 05/04/2006 | WO2005082042A3 Therapeutic methods employing nitric oxide precursors |
| 05/04/2006 | WO2005048944A3 Activatable photodynamic therapy agents |
| 05/04/2006 | WO2005033694A8 Novel antisense oligomers and use thereof |
| 05/04/2006 | WO2005025543A3 Polymer-based sustained release device and method for preparation |
| 05/04/2006 | WO2005007805A3 ANTISENSE ANTIVIRAL AGENT AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
| 05/04/2006 | WO2004093783A3 Modulation of apolipoprotein c-iii expression |
| 05/04/2006 | WO2004037972A3 Endogenous retrovirus up-regulated in prostate cancer |
| 05/04/2006 | WO2004013311A3 Compositions and methods relating to ovarian specific genes and proteins |
| 05/04/2006 | WO2003020911A3 Human schizophrenia gene |
| 05/04/2006 | US20060095984 Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| 05/04/2006 | US20060095075 Injection of fibrin sealant using reconstituted components in spinal applications |
| 05/04/2006 | US20060095016 Injection of fibrin sealant including an anesthetic in spinal applications |
| 05/04/2006 | US20060094862 Specificity exchangers that redirect antibodies to a pathogen |
| 05/04/2006 | US20060094682 administering a protein tyrosine kinase inhibitor such as bosutinib, or pyrido(2,3-d)pyrimidine drug known as PD 161570; drug screening; bioassays |
| 05/04/2006 | US20060094679 Method of preventing or treating liver disease |
| 05/04/2006 | US20060094665 Pharmaceutical angiostatic dipeptide compositions and methods of use thereof |
| 05/04/2006 | US20060094664 Deoxycholic acid derivatives for the treatment of acute dysfunctions of portal and hepatic venous circulation |
| 05/04/2006 | US20060094663 Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| 05/04/2006 | US20060094662 Pharmaceutical compositions for sustained drug delivery |
| 05/04/2006 | US20060094661 NY-ESO-1 peptide analogs |
| 05/04/2006 | US20060094660 Inhibitor of the shh signalling patway and a testosterone supressing agent for the treatment of cancer |
| 05/04/2006 | US20060094659 Peptides having sequences that substantially correspond to a specific region in N-terminal domain I of DBP can block DBP enhancement of C5a or C5a des Arg chemotactic activity; use thereof for the treatment C5a or C5a des Arg-mediated disorders such as immunoinflammatory disorders |
| 05/04/2006 | US20060094658 Method and compositions for the treatment of gastrointestinal disorders |
| 05/04/2006 | US20060094657 Inhibiting development of microvessels within coronary or peripheral vessel walls for restenosis/atherosclerosis prevention or therapy |
| 05/04/2006 | US20060094656 Method for fostering bone formation and preservation |
| 05/04/2006 | US20060094655 Modified growth hormones |
| 05/04/2006 | US20060094654 Neuroprotective complex for treatment of cerebral ischemia and injury |
| 05/04/2006 | US20060094653 Pancreatic polypeptide family motifs and polypeptides comprising the same |
| 05/04/2006 | US20060094652 Hybrid polypeptides with selectable properties |
| 05/04/2006 | US20060094651 Formulations and methods of production of FGF-20 |
| 05/04/2006 | US20060094650 Agent for improving life expectancy in therapy of malignant tumor |
| 05/04/2006 | US20060094649 Hla-a1,-a2,-a3,-a24,-b7, and-b44 tumor associated antigen peptides and compositions |